For researchers with existing cardiovascular disease, this regulatory distinction may be clinically relevant and worth discussing with their healthcare provider
While the test primarily assesses GLP-1 receptor, GIPR, FTO, and MC4R variants related to medication response, understanding your broader metabolic profileincluding factors like inflammation and glucose regulationmay inform your provider's injection strategy and timeline adjustments
Readers are advised to consult with a qualified healthcare professional for any medical concerns including side effects
However, their use in the perioperative period surrounding major surgeries, like total joint arthroplasty (TJA), remains an area of growing interest and concern
Understanding how GLP1R signalling protects the heart and blood vessels will optimize the therapeutic use and development of next-generation GLP1-based therapies with improved cardiovascular safety
Additional reporting by Jonathan Stempel and Christy Santhoshediting by Caroline Humer, Nia Williams and Susan Fenton)